Search

Global Health Watch: Global Fund replenishment, LEN for PrEP arrives, HIV funding uncertain post gov’t shutdown

This week’s newsletter publishes just as the Global Fund’s 8th Replenishment Summit in South Africa is taking place. The Global Fund represents one of the strongest symbols of global solidarity in the fight against HIV, TB, and malaria, but, despite early pledges from several European Union member states and private partners, key donors (including the UK, Germany and France) appear to be stepping back, with smaller or uncertain pledges at this critical moment, and it is not yet clear what the US will do.

Lenacapavir Regulatory Approval

Regulatory approvals, pending decisions, and appeals as of November 2025.

Community Engagement in USG Global Health MoUs

Global Health Watch: Pandemic Accord, US MoU pressure, LEN progress & UK Global Fund cuts

African countries reaffirm support for a new multilateral Pandemic Accord even as pressure mounts to sign bilateral US health agreements. The UK has reduced its upcoming Global Fund pledge just weeks before the replenishment summit. Meanwhile, additional regulatory submissions of LEN for PrEP are being made reflecting accelerated actions and real lessons learned from earlier PrEP rollout.

Cruel Ironies

We’re seeing one of the most challenging moments in HIV prevention history – and the cruelest ironies. On one side, science and advocacy are delivering unprecedented progress via injectable lenacapavir (LEN) for PrEP. On the other, the global systems meant to deliver LEN and other potential innovations are being dismantled.

Preparing for LEN

In the first year since efficacy results were reported, LEN for PrEP has achieved critical milestones in record time compared to oral PrEP, the dapivirine vaginal ring, and injectable cabotegravir. Speed, scale, and equity are still needed to deliver impact.

Global Health Watch: Zambia approves LEN, what “America First” means for global health, new documentary on impacts of foreign aid freeze

This week, Zambia joined South Africa in approving injectable lenacapavir for PrEP (LEN), marking a new era of accelerated efforts to scale-up access. At the same time, there’s sharpening analyses of the major shifts in US strategy for foreign aid and global health leadership, with deep implications for the future of funding, multilateralism, and equity.

Influencing the New USG Global Health MoUs and PEPFAR Strategy

New from AVAC

This round up offers on-the-ground tools for rolling out injectable lenacapavir; updates on AVAC’s court case on foreign assistance; resources on the state of defending rights to health and inclusion for key populations; a look at AVAC’s Advocacy Navigator program; updates on DPP at ICFP; and resources for cure research and the prevention of STIs.

Navigating Change